NEW YORK (GenomeWeb News) – The Jackson Laboratory said today that cancer biologist Edison Liu, current executive director of the Genome Institute of Singapore, will take over the top spot at the non-profit institute as its new president and CEO.
Liu founded the Singapore institute in 2001, and before that he was scientific director of the National Cancer Institute's Division of Clinical Sciences.
The Jackson Lab has been looking for a new leader since Rick Woychik departed last January to become deputy director of the National Institute of Environmental Health Sciences in Research Triangle Park, NC.
Singapore's Agency for Science, Technology, and Research (A*StAR) said separately today that Ng Huck Hui will step into Liu's shoes as the acting executive director of GIS in January. A*Star said that Hui, who joined GIS in 2003 has been "mentored and groomed" by Liu as part of a succession plan.
Liu started his career at the University of North Carolina at Chapel Hill, where he directed UNC's Lineberger Comprehensive Cancer Center's breast cancer research program and its Laboratory of Molecular Biology.
Kevin McKernan has founded Medicinal Genomics and is also now serving as its CEO. Most recently, he was the head of R&D for Ion Torrent at Life Technologies. He also served as Life Tech's vice president of advanced R&D and as a distinguished scientific fellow at Applied Biosystems.
McKernan also founded Agencourt Bioscience, which was subsequently acquired by Beckman Coulter, and Agencourt Personal Genomics, which was acquired by Applied Biosystems.
Complete Genomics has tapped Jill Hagenkord to be its chief medical officer and Keith Raffel as its chief commercial officer. Both of them will work to support the firm's services business and lead development of new genomic data and analysis products.
Hagenkord formerly was at the cancer diagnostics company iKaryos and an associate professor at Creighton University. Raffel previously was chairman and CEO of UpShot, a cloud computing company.
Enzo Biochem has added four executives to lead its Enzo Life Sciences subsidiary. The new team will focus on pharmaceutical and clinical applications.
Bruce Taillon has been named head of global technology business development. He previously worked at Roche 454 Life Sciences, where he was responsible for worldwide business development efforts centered on the company's next-generation sequencing platform and its potential use in diagnostic assays.
John D'Errico will lead Enzo Life Sciences' commercial merchandising operations. D'Errico joins Enzo from VWR Scientific, where he managed that company's life sciences product portfolio. Before that, he worked at Harvard Biosciences, where he headed business development efforts for the firm's Genomic Solutions business.
Kara Cannon has been appointed head of global marketing. She joins Enzo from Pall Corp., where she held executive positions in the areas of diagnostics, biotechnology, and biosciences.
Paul Munger has been tapped to lead Enzo Life Sciences' global manufacturing operations. He previously held an executive position at Pierce Chemical, now a division of Thermo Fisher Scientific, as well as a senior manufacturing management role at Transgenomic.
MDx Health said this week that Hilde Windels has resigned from its board of directors to avoid a conflict of interest due to her recent appointment as CFO of Biocartis. The company has appointed Ruth Devenyns as an independent director to replace Windels.
Promoted? Changing jobs? GenomeWeb wants to know. E-mail [email protected] to appear in People In The News, a weekly roundup of industry comings and goings.